High cobalamin levels as a five-year risk predictor for developing hematological cancer.

Area of Science:

• Clinical Biochemistry
• Hematology
• Oncology

Background:

• Elevated cobalamin (vitamin B12) levels have been associated with various non-malignant and malignant diseases.
• The predictive value of high cobalamin levels for future cancer development remains unclear.
• This study investigates the association between prior high cobalamin levels and subsequent cancer development over a five-year period.

Purpose of the Study:

• To determine if elevated cobalamin levels predict future cancer development within five years.
• To explore differences in cancer development between various cancer groups.
• To assess the clinical implications of hypervitaminosis B12 in cancer risk.

Main Methods:

• Retrospective study utilizing two databases from a hospital surveillance system.
• Inclusion of 6710 patients with cobalamin level determination in 2010 and subsequent five-year follow-up.
• Multivariate logistic regression analysis to evaluate the association between cobalamin levels and cancer incidence.

Main Results:

• A significant association was found between high cobalamin levels and the risk of hematological cancer.
• Patients with the highest cobalamin levels (over 779 pmol/L) had nearly double the risk of hematological malignancy within five years (OR: 1.975).
• No association was observed between high cobalamin levels and the development of other cancer types.

Conclusions:

• High plasma cobalamin levels (hypervitaminosis B12) are associated with an increased risk of hematologic cancer development within five years.
• Clinical suspicion and these findings support the need for specific hematological screening in patients with unexplained elevated cobalamin.
• Further prospective, multicenter studies are required to validate these findings.